Division of Thoracic Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Ann Thorac Surg. 2011 Nov;92(5):1780-6; discussion 1786-7. doi: 10.1016/j.athoracsur.2011.05.081. Epub 2011 Oct 31.
There are few data to predict the benefit of pulmonary metastasectomy in patients with extrathoracic sarcoma. This study analyzes prognostic factors associated with improved outcomes.
Between June 2002 and December 2008, 97 patients underwent pulmonary resection for metastatic sarcoma at Massachusetts General Hospital. Eight patients were excluded because of lack of follow-up data. Analysis was performed using Kaplan-Meier estimates of survival, log-rank test, and multivariate Cox model.
Overall 5-year survival for the cohort was 50.1%. Patients who had multiple operations for recurrent pulmonary metastases had better 5-year survival compared with patients who had a single operation (69 versus 41%; p = 0.017). Median disease- free survival (DFS) for the reoperation group was 12.9 months compared with 9.1 months for the single-operation group (p < 0.028). Patients with a disease-free interval (DFI) greater than 12 months from detection of primary sarcoma to pulmonary metastasectomy had improved survival compared with those whose DFI was less than 12 months (p < 0.0001). Patients with bilateral metastasectomy had lower 5-year survival compared with metastasectomy for unilateral disease (22% versus 68% ;p < 0.0001). Two or more metastases were associated with poorer outcome compared with a single metastasis (p = 0.0007). A positive resection margin portended worse survival compared with a negative resection margin (p = 0.004). Patients with lesions larger than 3 cm had decreased survival compared with patients with lesions smaller than 3 cm (p = 0.017) with no difference in median DFS. Histologic type, grade of tumor, and use of chemotherapy had no effect on survival. Multivariate analysis showed that patients with a DFI greater than 12 months (p = 0.001), single-sided metastasis (p = 0.001), negative margins (p = 0.002), and multiple operations (p = 0.018) had better survival.
Pulmonary metastasectomy for sarcoma can be associated with prolonged survival. Tumor resectability, DFI, number of metastases, and laterality are important factors in determining patient selection for curative surgical intervention. Repeated pulmonary metastasectomy in select patients may improve survival despite recurrent disease.
目前仅有少量数据可用于预测胸外肉瘤患者肺转移切除术的获益,本研究旨在分析与改善预后相关的预测因素。
2002 年 6 月至 2008 年 12 月,在马萨诸塞州综合医院接受肺转移切除术的 97 例肉瘤患者,其中 8 例因缺乏随访数据被排除。采用 Kaplan-Meier 生存估计、对数秩检验和多变量 Cox 模型进行分析。
该队列的总体 5 年生存率为 50.1%。与接受单次手术的患者相比,接受多次复发性肺转移切除术的患者的 5 年生存率更高(69%比 41%;p = 0.017)。再次手术组的中位无疾病生存(DFS)期为 12.9 个月,而单次手术组为 9.1 个月(p < 0.028)。与无疾病间隔(DFI)小于 12 个月的患者相比,DFI 大于 12 个月的患者的生存情况更好(p < 0.0001)。与单侧疾病相比,双侧肺转移切除术患者的 5 年生存率较低(22%比 68%;p < 0.0001)。与单发转移相比,2 个或更多转移与较差的预后相关(p = 0.0007)。切缘阳性预示着生存情况更差(p = 0.004)。与病灶小于 3cm 的患者相比,病灶大于 3cm 的患者的生存率降低(p = 0.017),但中位 DFS 无差异。组织学类型、肿瘤分级和化疗的使用对生存没有影响。多变量分析显示,DFI 大于 12 个月(p = 0.001)、单侧转移(p = 0.001)、阴性切缘(p = 0.002)和多次手术(p = 0.018)的患者生存情况更好。
肉瘤肺转移切除术可延长生存时间。肿瘤可切除性、DFI、转移灶数量和肿瘤侧别是确定患者接受根治性手术干预的重要因素。尽管疾病复发,选择合适的患者进行多次肺转移切除术可能会改善生存。